Primary hyperaldosteronism: A frequent cause of residual hypertension after successful endovascular treatment of renal artery disease

Journal of Hypertension

Volumn 23, Issue 11, 2005, Pages 2041-2047

  Pizzolo, Francesca ^a   Pavan, Chiara ^a   Guarini, Patrizia ^a   Trabetti, Elisabetta ^a   Girelli, Domenico ^a   Corrocher, Roberto ^a   Olivieri, Oliviero ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b POLICLINICO BORGO ROMA   (Italy)

Author keywords

Aldosterone to renin ratio; Hypertension; Primary hyperaldosteronism; Renal artery disease

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOVASCULAR SURGERY; FEMALE; HUMAN; HYPERTENSION; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; REVASCULARIZATION;

EID: 29244434829     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000187260.32567.75     Document Type: Article

References (37)

1. Safian RD, Textor SC. Renal artery stenosis. N Engl J Med 2001; 344:431-442.
2. Plouin PF, Chatellier G, Darne' B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Hypertension 1998; 31:823-829.
3. Jaarsveld BC, Krijen P, Pieterman H, Derkx FHM, Deinum J, Postma CT, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal artery stenosis. N Engl J Med 2000; 342:1007-1014.
4. Webster J, Marshall F, Abdalla M, Dominiczak A, Edwards R, Isles CG, et al. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12:329-325.
5. Radermacher J, Weinkove R, Haller H. Techniques for predicting a favourable response to renal angioplasty in patients with renovascular disease. Curr Opin Nephrol Hypertens 2001; 10:799-805.
6. Gordon RD, Ziezak MD, Tunny TJ, Stowasser M, Klemm SA. Evidence that primary aldosteronism may not be uncommon - twelve percent incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20:296-298.
7. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, et al. Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000; 85:1863-1867.
8. Stowasser M, Gordon RD. Prevalence and diagnostic workup of primary aldosteronism: new knowledge and new approaches. Nephrology 2001; 6:119-126.
9. Young WF. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 114:2208-2213.
10. Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, et al. Aldosterone to renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89:4221-4226.
11. Mann SJ, Pickering TG. Detection of renovascular hypertension. Ann Intern Med 1992; 117:845-853.
12. Glodny B, Cromme S, Wortler K, Herwig R, Kisters K, Winde G. Conn's syndrome and bilateral renal artery stenosis in the presence of multiple renal arteries. J Endocrinol Invest 2001; 24:268-273.
13. Mansoor GA, Tendler BE, Anwar YA, Uwaifo G, White WB. Coexistence of atherosclerotic renal artery stenosis with primary aldosteronism. J Hum Hypertens 2000; 14:151-153.
14. Chowdhury TA, Lasker SS. Coexisting renal artery stenosis and primary aldosteronism. Nephrol Dial Transplant 1997; 12:2735-2736.
15. Stokes GS, Monaghan JC, Roche J, Grunstein H, Gordon RD. Concurrence of primary aldosteronism and renal artery stenosis. Clin Exp Pharmacol Physiol 1992; 19:300-303.
16. Cheung YK, Chan FL, Lam KS. Aldosteronoma coexisting with renal artery stenosis in secondary hypertension. Urol Radiol 1992; 13:228-232.
17. Santangelo K, Cheung JY, Gifford RR, Thiele BL, Yang HC. The simultaneous occurrence of renal artery stenosis and an aldosteronoma in a patient with hypertension. Am J Kidney Dis 1989; 14:520-523.
18. Christenson WB, Kauman JJ, Gonick HC. Co-existing aldosterone-producing adrenal tumor (aldosteronoma) and bilateral renovascular lesions. J Urol 1969; 101:1-7.
19. Bloch HS. Hypertension, bilateral renal artery stenosis, adrenocortical adenomas, and normal serum electrolyte levels. JAMA 1966; 196:622-624.
20. Beevers DG, Brown JJ, Ferriss JB, Fraser R, Lever AF, Robertson JI, et al. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. OJM 1976; 45:401-410.
21. Olivieri O, Bassi A, Stranieri C, Trabetti E, Martinelli N, Pizzolo F, et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003; 44:2374-2381.
22. Olivieri O, Bassi A, Pizzolo F, Tinazzi E, Corrocher R. Cystatin C versus creatinine in renovascular disease. Clin Chem 2002; 48:2256-2259.
23. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6:717-723.
24. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 1971; 128:380-386.
25. Stowasser M, Gordon RD, Klemm SA, Tunny TJ. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis. J Clin Endocrinol Metab 1993; 77:800-804.
26. MacConnachie AA, Kelly KF, McNamara A, Loughlin S, Gates LJ, Inglis GC, et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J Clin Endocrinol Metab 1998; 83:4328-4331.
27. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29-34.
28. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol 2000; 54:203-209.
29. Derkx FH, Schalekamp MA. Renal artery stenosis and hypertension. Lancet 1994; 344:237-239.
30. Eardley KS, Lipkin GW. Atherosclerotic renal artery stenosis: is it worth diagnosing? J Hum Hypertens 1999; 13:217-220.
31. Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH. Pseudo-primary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 1970; 27(Suppl 1):203-220.
32. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
33. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16(11 Pt 1):925-930.
34. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 2004; 125:112-117.
35. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226.
36. Conn JW, Cohen EL, Rovner DR. Suppression of plasma renin activity in primary aldosteronism. JAMA 1964; 190:213-221.
37. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, et al. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40:897-902.